BromSite(InSite Vision) success in Phase III trial for Cataract Surgery
InSite Vision Incorporated has announced top-line results from its recently completed Phase III clinical trial of BromSite(ISV-303) for the reduction of inflammation and pain after Cataract Surgery. BromSite achieved statistically significant superiority compared to vehicle in alleviating ocular pain and inflammation among patients following Cataract Surgery. InSite Vision plans to rapidly initiate the second Phase III trial of BromSite in order to be prepared to file for regulatory approvals in both the United States and Europe as soon as possible after the completion of that trial.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins